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Letter to Editor
Evaluation of the metformin effects
on Anti-Müllerian Hormone in women
with polycystic ovarian syndrome:
A double-blind randomized clinical trial
Dear Editor,
Anti-Müllerian hormone (AMH) is made by the granulosa cells of preantral and small
antral follicles which blocks the transition from the primordial to the primary follicular
stage. Metformin may be associated with a decrease in AMH serum level and antral
follicles in women who suffer from polycystic ovary syndrome (PCOs)
It was reported that metformin in women with polycystic ovary syndrome (PCOs) is
associated with a decrease in both AMH serum level and antral follicles.
The objective of the current letter was the evaluation of the effects of metformin
on hormonal profile of women with PCOs. In this prospective, randomized, double-
blind controlled clinical trial, 42 women (aged 17–45 yr) with PCOs who were randomly
allocated to receive 500 mg Metformin orally three times a day or placebo for
three months were included. Fasting plasma glucose, follicular stimulating hormone,
luteinizing hormone (LH), prolactin (PRL), testosterone and AMH levels were measured
at baseline and at the end of the period. In this study, independent and paired t-test
were used for quantitative comparison and chi-square analysis for qualitative variables.
Logistic regression analysis was done to identify independent risk factors, and P-
value of lower than 0.05 were considered significant. All of the statistical analyses
were done by SPSS software, version 20.0. We didn’t find any significant change
after the study between treatment and control groups in hormonal profiles especially
AMH. However, in subgroup analysis, we revealed that AMH and LH levels decreased
significantly in normal weight patients (p= 0.024, 0.048, respectively) and prolactin
levels in subgroup of overweight patients (p= 0.001). Moreover, patients in metformin
group at the end of study had more regular menses, more weight loss, and lower
hair loss (p= 0.001, 0.04, 0.014, respectively). Women with PCOs have elevated levels
of LH that is secondary to increased sensitivity of pituitary to GnRH. Increased levels
of LH lead to hyperandrogenism. Metformin can improve this condition. In this study,
we observed that LH was decreased significantly in the metformin group of PCOs
patients (p= 0.05). It is in agreement with some of the previous studies, however, De
Leo and et al. reported a non-significant decrease in LH levels after treatment with
metformin (1). Pieces of evidence showed that AMH levels in PCOs patients are 2 to 3
times higher than age-matched normal women (2), and this condition is a marker for
PCOs and can be a surrogate test of hyperandrogenism (3). Metformin in our study
improved the irregularity in the menstrual cycle (p< 0.001), hair loss (p= 0.014), and
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prolactin secretion (p= 0.024), as well as LH secretion (p= 0.05); however, it didn’t
show any significant decrease on AMH levels. Metformin can reduce ovarian volume
in PCOs patients especially in hyperinsulinemic subgroups (4); however, we observed
that in normal weight subgroup of patients, metformin decreased AMH significantly
(p= 0.024), and in overweight or obese patients, prolactin decreased in response
to metformin, significantly (p= 0.001). Moreover, metformin leads to improvement in
follicular development with fewer percentage of preantral follicles and cysts and higher
percentages of antral follicles (5). Considering these pieces of evidence, it seems that
AMH after metformin treatment in PCOs patients was secret in comparable amounts of
pretreatment; however, the source of secretion after starting metformin is different from
pretreatment and switched from small follicles and cysts to more developed follicles
and structures such as antral follicles and corpora lutea. Further investigations that can
differentiate secreted AMH from a different source will shed more light on this field.
The most important limitation of our study is the small sample size. GI side effects of
metformin caused some patients in metformin group to refuse getting the treatment.
Studies with more attendants can display the difference between different phenotypes
of PCOs patients in response to metformin. In conclusion, this study showed that
metformin can cause favorable effects on the hormonal profile of PCOs patients, and
although AMH levels were not decreased significantly, menstruation improved in the
treated group.
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